Swiss Spiez Laboratory finds potential plant-based treatment for SARS-nCOV-2 Virus
In the current study, we have shown that four human
coronaviruses (HCoV-229E, MERS-CoV, SARS-CoV-1
and SARS-CoV-2) are inactivated by Echinaforce
in vitro, further strengthening its use as a prophylactic
treatment against a wide range of respiratory viruses
causing either serious pulmonary disease or the common
cold. Furthermore, a broadly acting antiviral compound
suitable for long-term prophylaxis upon exposure could
be beneficial to health care workers treating severe CoV
infections and potentially reduce the transmission and
morbidity of highly pathogenic coronaviruses in the general population. Due to its general mode of action, novel
zoonotic coronaviruses, as shown for SARS-CoV-2,
could also be sensitive to Echinaforce, potentially providing an accessible and inexpensive prophylactic treatment
for other emerging coronavirus infections.
Attached PDF source:
https://virologyj.biomedcentral.com/track/pdf/10.1186/s12985-020-01401-2
More information about the Spiez Laboratory:
https://www.labor-spiez.ch/en/lab/